))
“The Heart Will Go On”: Recent Updates in the Treatment of HFpEF
Manage episode 319299202 series 2908322
Contenuto fornito da Mayo Clinic. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Mayo Clinic o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Divya A. Khandekar, Pharm.D., M.S., compares and contrasts the etiologies of heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF), discusses primary literature examining current treatment options for HFpEF and identifies the role of SGLT2 inhibitors in the treatment of HFpEF.
For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!
You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.
101 episodi
Condividi
